Birmingham University Department of Vascular Surgery, Flat 5 Netherwood House, Solihull Hospital, Lode Lane, Solihull B91 2JL, UK.
Br J Surg. 2014 Aug;101(9):1098-104. doi: 10.1002/bjs.9581. Epub 2014 Jun 24.
The aim was to determine the long-term (5-8 years) outcomes of ultrasound-guided foam sclerotherapy (UGFS) for varicose veins using health-related quality of life (HRQL), patient-reported outcomes (PROMs), patient satisfaction and retreatment rates.
Consecutive patients undergoing UGFS between April 2004 and May 2007 were invited for review at least 5 years after treatment. Patients completed generic (Short Form 12) and disease-specific (Aberdeen Varicose Vein Symptom Severity Score, AVSS) HRQL instruments, and questionnaires enquiring about lower limb symptoms, lifestyle factors and satisfaction with treatment. Data on retreatments were recorded prospectively.
A total of 391 limbs in 285 patients were included (81·2 per cent response rate) at a median of 71 (i.q.r. 67-78) months following first UGFS treatment. Originally 72·1 per cent had symptomatic, uncomplicated varicose veins, 21·9 per cent had undergone surgery previously, 87·2 per cent had treatment of great saphenous veins and 19·9 per cent treatment of short saphenous veins. Disease-specific HRQL scores improved significantly at long-term follow-up, with 88·5 per cent having an improved AVSS compared with baseline. Regarding lower limb symptoms and lifestyle improvement, 62·7-93·8 per cent of patients had their pretreatment expectations met or exceeded. Overall, 82·0 per cent were very satisfied with their treatment and only 3·3 per cent were dissatisfied; 91·0 per cent would recommend the treatment to others. Some 15·3 per cent of limbs required retreatment by 5 years (Kaplan-Meier analysis).
UGFS has durable results as reported by PROMs to at least 5 years. Only 15·3 per cent of limbs required retreatment for recurrence during follow-up.
本研究旨在通过健康相关生活质量(HRQL)、患者报告结局(PROM)、患者满意度和再治疗率来确定超声引导下泡沫硬化疗法(UGFS)治疗静脉曲张的长期(5-8 年)疗效。
2004 年 4 月至 2007 年 5 月期间接受 UGFS 的连续患者在治疗后至少 5 年被邀请进行复查。患者完成了通用(SF-12)和疾病特异性(Aberdeen 静脉曲张症状严重程度评分,AVSS)HRQL 量表,以及关于下肢症状、生活方式因素和对治疗满意度的问卷。前瞻性记录了再治疗数据。
共有 285 名患者的 391 条肢体(81.2%的应答率)在首次 UGFS 治疗后中位数为 71(IQR 67-78)个月时纳入研究。最初,72.1%的患者患有有症状、无并发症的静脉曲张,21.9%的患者以前接受过手术治疗,87.2%的患者接受了大隐静脉治疗,19.9%的患者接受了小隐静脉治疗。在长期随访中,疾病特异性 HRQL 评分显著改善,88.5%的患者与基线相比 AVSS 得到改善。在下肢症状和生活方式改善方面,62.7%-93.8%的患者满足或超过了他们的治疗预期。总体而言,82.0%的患者对治疗非常满意,只有 3.3%的患者不满意;91.0%的患者会向他人推荐这种治疗方法。在 5 年时,约 15.3%的肢体需要再次治疗(Kaplan-Meier 分析)。
UGFS 的 PROM 结果至少在 5 年内具有持久疗效。在随访期间,只有 15.3%的肢体因复发需要再次治疗。